Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Change in Inventory (2019 - 2025)

Catalyst Pharmaceuticals' Change in Inventory history spans 7 years, with the latest figure at $9.2 million for Q4 2025.

  • For Q4 2025, Change in Inventory rose 2036.97% year-over-year to $9.2 million; the TTM value through Dec 2025 reached $18.1 million, up 364.18%, while the annual FY2025 figure was $18.1 million, 364.18% up from the prior year.
  • Change in Inventory reached $9.2 million in Q4 2025 per CPRX's latest filing, up from $9.1 million in the prior quarter.
  • In the past five years, Change in Inventory ranged from a high of $9.2 million in Q4 2025 to a low of -$1.9 million in Q2 2024.
  • Average Change in Inventory over 5 years is $1.4 million, with a median of -$10000.0 recorded in 2022.
  • The largest YoY upside for Change in Inventory was 2121.1% in 2023 against a maximum downside of 1241.86% in 2023.
  • A 5-year view of Change in Inventory shows it stood at $920000.0 in 2021, then crashed by 135.54% to -$327000.0 in 2022, then skyrocketed by 2121.1% to $6.6 million in 2023, then tumbled by 107.2% to -$476000.0 in 2024, then surged by 2036.97% to $9.2 million in 2025.
  • Per Business Quant, the three most recent readings for CPRX's Change in Inventory are $9.2 million (Q4 2025), $9.1 million (Q3 2025), and -$455000.0 (Q2 2025).